Treatment Patterns of Real-World Patients with TRK Fusion Cancer Treated by US Community Oncologists.

ABSTRACT:

Background

 Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are present across various tumor types with an estimated overall prevalence of less than 1%. Tropomyosin receptor kinase inhibitors (TRKis) block the constitutively activated tyrosine receptor kinase (TRK) fusion protein produced in cancers with NTRK gene fusions (NTRK+) from downstream signaling. Many treatment guidelines now include TRKis as first-line (1L) or subsequent treatment options for TRK fusion cancer.

Objective

This study aimed to assess treatment patterns subsequent to a finding of NTRK+ status among patients with TRK fusion cancer.

Patients and methods

This was a one-time, retrospective, multi-site patient chart abstraction by oncology practices in the USA from June to September 2020.

SUBMITTER: Klink AJ 

PROVIDER: S-EPMC9512741 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature